Cord Blood News 10.41 October 18, 2018 | |
| |
TOP STORYAfter autologous stem cell transplantation, neutrophil recovery was similar, while platelet recovery was delayed in 131Iodine-meta-iodobenzylguanidine (131I-MIBG)- compared to chemotherapy-only-treated patients. Testing of harvested CD34+ cells revealed a reduced post-thaw viability in the 131I-MIBG-group. [Clin Cancer Res] Abstract | Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers investigated the thermo sensitivity of Wharton’s jelly MSCs (WJ-MSCs) from human umbilical cord to elevated temperature in the physiological fever range. They explored the effect of febrile range temperature on morphology, viability, proliferation kinetics and cell cycle status of WJ-MSCs. [Stem Cells Dev] Abstract Automated Thawing Increases Recovery of Colony-Forming Units from Banked Cord Blood Unit Grafts Post thaw recoveries can be improved by washing cord blood units in dextran/albumin. Investigators recently developed and validated an automated washing method. In this study, they compared cellular recoveries achieved after manual and automated wash, as well as the impact on engraftment following allogeneic transplantation. [Transfusion] Abstract As compared with cells in synthesis(S)/Gap2(G2)/mitosis(M), cells in quiescent state(G0)/Gap1(G1) showed a higher proliferation potential in vitro. Treatment with hydroxyurea before culture resulted in an increase in the proportion of cells in G1 with a concomitant decrease in S/G2/M cells, without affecting the proportion of cells in G0. [Cytotherapy] Abstract Researchers demonstrated that functional cardiomyocytes could be generated from human umbilical cord-derived cells. Spontaneous beating colonies were observed at day seven after the sequential addition of CHIR99021 and IWP-4. [J Cell Biochem] Abstract Lung injury was significantly alleviated in rats treated with human umbilical cord MSCs (hUCMSCs). hUCMSCs overexpressing SOD2 were more effective in reducing PQ-induced lung injury in rats compared with hUCMSCs only. [Life Sci] Abstract Subscribe to one of our other 19 science newsletters such as Hematopoiesis News & Cell Therapy News. | |
| |
REVIEWSUmbilical Cord Blood as a Source for Red-Blood-Cell Transfusion in Neonatology: A Systematic Review The authors revise the literature concerning the use of umbilical cord blood (UCB) for either autologous or allogeneic transfusion purposes, and illustrate the rationale for a transfusion therapy tailored to extremely preterm neonates, based on red blood cell concentrates from allogeneic UCB donations. [Vox Sang] Full Article Visit our reviews page to see a complete list of reviews in the cord blood research field. | |
| |
INDUSTRY NEWSMaaT Pharma announced the dosing of the first patient in a Phase II clinical trial of its lead microbiome restoration candidate, MaaT013, in patients with steroid-resistant acute Graft-versus-Host-Disease. [MaaT Pharma] Press Release Cellect Announces Positive Clinical Results Cellect Biotechnology Ltd. announced further data from a Phase I/II study of its ApoGraft™ technology. With half of the patients planned for the study having finished first month follow up, all such patients have shown 100% engraftment with no procedure related adverse events reported. [Cellect Biotechnology Ltd. (PR Newswire Association LLC.)] Press Release Cellenkos, Inc. announced that the FDA has cleared its Investigational New Drug application to proceed with a Phase I clinical trial of CK0801, allogeneic cord blood-derived regulatory T cells, in patients with treatment-resistant Guillain-Barré Syndrome. [Cellenkos, Inc. (PR Newswire Association LLC.)] Press Release FDA Grants Breakthrough Therapy Designation to Kadmon’s KD025 for Chronic Graft-Versus-Host Disease Kadmon Holdings, Inc. announced that the FDA has granted Breakthrough Therapy Designation to KD025, the company’s ROCK2 inhibitor, for the treatment of patients with chronic graft-versus-host disease after failure of two or more lines of systemic therapy. [Kadmon Holdings, Inc.] Press Release | |
| |
POLICY NEWSBeset by economic woes and dissatisfied with the left-wing politicians in power for most of the past 15 years, Brazil appears poised to make a hard turn and elect a far-right candidate, Jair Bolsonaro, as its next president. His rapid ascent has unnerved local researchers, who worry about the future of Brazilian science, the protection of the country’s biodiversity, and its role in the global struggle against climate change. [ScienceInsider] Editorial Outsider Takes Helm at Indian Research Giant Shekhar Mande, a structural biologist, took over as director-general of India’s Council of Scientific and Industrial Research (CSIR), headquartered in New Delhi, which operates a network of 40 research labs around the country. Mande is the first outsider to take on the top job at CSIR since 1984. [ScienceInsider] Editorial Researchers behind Biogen’s Breakthrough Drug Win Big at ‘Oscars of Science’ Two scientists behind Biogen’s rare disease treatment Spinraza won the richest award in the life sciences, splitting a $3 million prize and a turn on stage at a star-studded ceremony next month. [STAT News] Editorial
| |
EVENTSNEW 45th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Research Fellow – Stem Cell Biology & Engineering (New York Blood Center) Postdoctoral Fellow – Blood Development & Disease (University of Washington) Senior Research Assistant – Stem Cell Transplantation (MD Anderson Cancer Center) Postdoctoral Associate – Hematopoiesis and Leukemia (The Jackson Laboratory) Postdoctoral Fellowship – Translational Leukemia (Lund University) Postdoctoral Fellow – Myelodysplasia and Acute Myeloid Leukemia (UNSW) Professorship – Somatic Gene Therapy (University of Zurich) Bioinformatician – Single Cell Biology and Reprogramming (Lund University Stem Cell Center) Postdoctoral Researcher – Interdisciplinary (Oregon Health & Science University) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cord Blood News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|